A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma.

Trial Profile

A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Mapatumumab (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Human Genome Sciences
  • Most Recent Events

    • 14 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2017 Planned End Date changed from 1 Dec 2017 to 29 Dec 2017.
    • 10 Aug 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top